First Manhattan CO Aerie Pharmaceuticals Inc Transaction History

First Manhattan CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$13.12 - $20.9 $5.96 Million - $9.49 Million	-454,216 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$9.12 - $14.49 $220,247 - $349,933	-24,150 Reduced 5.05%	454,216 $6.14 Million
Q3 2020 Nov 12, 2020	SELL	$10.46 - $14.46 $1.3 Million - $1.8 Million	-124,500 Reduced 20.65%	478,366 $5.63 Million
Q2 2020 Aug 14, 2020	SELL	$12.0 - $16.13 $6.34 Million - $8.52 Million	-527,929 Reduced 46.69%	602,866 $8.9 Million
Q1 2020 May 06, 2020	BUY	$11.84 - $25.52 $5.95 Million - $12.8 Million	502,700 Added 80.04%	1,130,795 $15.3 Million
Q4 2019 Feb 13, 2020	BUY	$17.72 - $25.1 $948,905 - $1.34 Million	53,550 Added 9.32%	628,095 $15.2 Million
Q3 2019 Nov 13, 2019	BUY	$18.41 - $28.0 $10.6 Million - $16.1 Million	574,545 New	574,545 $11 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

Stay updated on First Manhattan CO with notifications on news.